balcinrenone

Balcinrenone (AZD9977) is a first-in-class, non-steroidal selective mineralocorticoid receptor (MR) modulator developed by AstraZeneca. It is designed to provide the cardiorenal benefits of MR antagonism—such as reducing inflammation and fibrosis—while minimizing the risk of hyperkalemia, a common and potentially life-threatening side effect associated with traditional steroidal MR antagonists like spironolactone and eplerenone. Balcinrenone exhibits a distinct binding mode and recruitment of coregulators compared to traditional MRAs, acting as a partial antagonist or modulator. It is primarily being investigated for the treatment of chronic kidney disease (CKD) and heart failure, often in combination with SGLT2 inhibitors like dapagliflozin to enhance therapeutic efficacy and safety profiles in patients with cardiorenal metabolic conditions.

Other names

balcinrenone